Cynthia Tang  ORCID iD: 0000-0001-5272-7170
Jun Hang  ORCID iD: 0000-0002-6597-7045

SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing

Shortened Title: Losing infectivity in prolonged COVID-19

Xiu-Feng Wan 1,2,3,4,5, Cynthia Y. Tang 1,2,3,5, Detlef Ritter 6, Yang Wang 1,2,3,5, Tao Li 7, Karen Segovia 1,2,3,5, Martina Kosikova 8, Marc Johnson 2, Hyung Joon Kwon 8, Hang Xie 8, Richard D. Hammer 6, Jane A. McElroy 9, Aws Hamid 10, Natalie D Collins 7, Jun Hang 7, Simone Camp 6

1MU Center for Influenza and Emerging Infectious Diseases, University of Missouri, Columbia, Missouri, USA; 2Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, Missouri, USA; 3Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA; 4Department of Electrical Engineering & Computer Science, College of Engineering, University of Missouri, Columbia, Missouri, USA; 5MU Institute for Data Science and Informatics, University of Missouri, Columbia, Missouri, USA; 6Department of Pathology, University of Missouri, Columbia, Missouri, USA; 7Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 8Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA; 9Department of Family Medicine, School of Medicine, University of Missouri, Columbia, Missouri, USA; 10Department of Radiology, School of Medicine, University of Missouri, Columbia, Missouri, USA.

Corresponding Author:
Dr. Xiu-Feng Wan
University of Missouri-Columbia
1201 Rollin Street
Columbia, MO 65211
+1-573-882-8943
wanx@missouri.edu

Abstract

Inpatient COVID-19 cases present enormous costs to patients and health systems in the United States. Many hospitalized patients may continue testing COVID-19 positive even after resolution of symptoms. Thus, a pressing concern for clinicians is the safety of discharging these asymptomatic patients if they have any remaining infectivity. This case report explores the viral viability in a patient with persistent COVID-19 over the course of a two-month hospitalization. Positive nasopharyngeal swab samples were collected and isolated in the laboratory and analyzed by quantitative reverse transcription polymerase chain reactions (qRT-PCR), and serology was tested for neutralizing antibodies throughout the hospitalization period. The patient experienced waning symptoms by hospital day 40 and had no viable virus growth by hospital day 41, suggesting no risk of infectivity, despite positive RT-PCR results which prolonged his hospital stay. Notably, this case showed infectivity for at least 24 days after disease onset.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.27001.

This article is protected by copyright. All rights reserved.
which is longer than the discontinuation of transmission-based precautions recommendation by the CDC. Thus, our findings suggest that the timeline for discontinuing transmission-based precautions may need to be extended for patients with severe and prolonged COVID-19 disease. Additional large-scale studies are needed to draw definitive conclusions on the appropriate clinical management for these patients.

**Key Words:** COVID-19, SARS-CoV-2, Inpatients, Patient Discharge, Real-Time Polymerase Chain Reaction

**INTRODUCTION**

On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) a pandemic. COVID-19, caused by order *nidovirales*, family *coronaviridae*, genus *betacoronavirus*, species *severe acute respiratory syndrome coronavirus* 2 (SARS-CoV-2), has cause more than 128 million laboratory-confirmed infections worldwide as of March 31, 2021. Inpatient COVID-19 hospitalizations were projected to cost the United States healthcare system up to $16.9 billion in 2020 and impose a large financial burden to individual patients. The median hospital stay for COVID-19 was 10-14 days in the United States. Many hospitalized patients with prolonged viral shedding may test COVID-19 positive even after resolution of symptoms and infectivity, causing a prolonged hospitalization. In addition to measuring viral load, serological tests measuring antibody responses against SARS-CoV-2 are also valuable diagnostic tools. SARS-CoV-2 specific antibodies against the receptor binding domain (RBD), nucleocapsid (N), and spike (S) antigens vary over time, correspond to disease severity, and peak one to two months after symptom onset. Neutralizing antibodies (Nabs), which function to bind to infectious viruses and minimize virus pathogenesis, have been shown to persist over three months, but also can rapidly decline within two months. Thus, a pressing concern for clinicians is gauging the safety of discharging these asymptomatic patients: whether they have any remaining infectivity and whether they are adequately protected from additional infection.

As of August 2020, the Center for Disease Control and Prevention (CDC) no longer recommends test-based strategies due to prolonged and detectable shedding in patients that no longer have infectivity. The CDC recommends the following guidelines for the discontinuation of transmission-based precautions for persons with severe or critical illness: patients may be discontinued from transmission-based precautions up to 20 days after symptom onset, at least 24 hours after the last fever, and improved symptoms. In this case report, we present a patient with critical severity of COVID-19 disease who was still shedding infectious viruses at 24 days after symptom onset during his two-month long hospitalization.

**METHODS**

**Ethics statement.** This study was performed under the Institutional Review Board (#2023844) and the Biosafety Level 3 (#20-14), in compliance with the Institutional Biosafety Committee of the University of Missouri-Columbia.

**Sample Collection.** The patient’s clinical observations were documented at least twice daily and multiple nasopharyngeal swabs and plasma samples were collected and tested to determine viral loads and Nab titers. Periodic national early warning scores (NEWS) were assessed. A score of seven or higher identifies high risk patients requiring activation of a medical emergency team. The patient’s NEWS scores were between eight and
twelve from Day 33 through Day 45 and then remained below seven from Day 46 until discharge.

**COVID-19 diagnosis.** COVID-19 was diagnosed using the 2019 Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT)–PCR Diagnostic Panel from the International Reagent Resource. A threshold cycle (Ct-value) below 40 is considered COVID-19 positive. Four positive samples were collected throughout the patient’s hospital stay, and three samples were successfully recovered for analysis.

**Tissue culture infectious dose (TCID<sub>50</sub>).** To test the viability of live virus in each of the viral samples at different time points of the patient’s hospitalization, the viral samples were serially diluted from 1:10<sup>1</sup> to, at most, 1:10<sup>12</sup> in Opti-Minimal Essential Medium Reduced-Serum Medium. 200µL of diluted virus was placed in four wells of Vero E6 cells that were seeded in 96-well plates for each dilution for 1 day and incubated at 37°C in 5% CO<sub>2</sub> for 3 days. Cytopathic effects were recorded. TCID<sub>50</sub> represents the viral loads causing a cytopathic effect in 50% of the wells as calculated by the Reed-Muench method<sup>13</sup>. Additional methods are available in the supplementary file.

**RESULTS**

**COVID-19 Disease Course.** In March 2020, a 65-year-old Caucasian male presenting to Urgent Care with fever, weakness, fatigue, rhinorrhea, and cough was diagnosed SARS-CoV-2 positive three days after disease onset. The patient had recently returned from Europe and had comorbidities of hypertension, hyperlipidemia, and prediabetes. He did not have any pre-existing conditions causing him to be immunocompromised. Four days later (7 days after disease onset), the patient was admitted to University of Missouri Health Care Hospital (Day 1) with increased shortness of breath (Figure 1A). X-ray revealed bilateral, patchy ground glass opacities consistent with viral pneumonia. Hydroxychloroquine and broad-spectrum antibiotics were initiated during the first week of admission.

On Day 2 (D2), the patient developed acute hypoxic respiratory failure and was transferred to the Intensive Care Unit (ICU), requiring endotracheal intubation, mechanical ventilation, and intermittent vasopressors. His hospital course was complicated by secondary bacterial pneumonia, eosinophilic bronchiolitis, and oral candidiasis. A computerized tomography (CT) scan performed on D29 showed extensive diffuse bilateral ground glass opacities and subpleural consolidation consistent with COVID-19-associated respiratory failure (Figure 1B). A percutaneous endoscopic gastrostomy and tracheostomy were placed on D32 and D33, respectively. The patient had another fever on D36-38 due to Klebsiella pneumonia which was treated with broad spectrum antibiotics. A follow-up CT chest scan on D40 showed interval improvement in the airspace opacities (Figure 1B).

**Nasopharyngeal swab test results.** Viral RNA was undetectable on D51 and inconclusive on D52. An inconclusive PCR result indicated that one of the controls from the PCR test was unsuccessful. Thus, an additional nasopharyngeal swab performed the following day (D53) and was positive again. A follow-up nasopharyngeal swab was collected and was still positive on D57 with markedly increased viral RNA load (Figure 1C). On D61 and D62, two nasopharyngeal swabs revealed undetectable viral RNA. The patient was discharged on D63 in stable condition.
**Genome sequencing and elevated viral load.** Due to the positive-negative-positive results of this patient, the viruses were recovered and sequenced using one-step RT-PCR amplification with an integrated microfluidic system and next-generation sequencing\(^\text{14}\) (supplementary methods) to check for reinfection. Viruses were recovered from the clinical samples collected on D17 (Sample 1, threshold cycle [Ct] = 32.5), which was 24 days post disease onset. The sequences recovered for Sample 20x1087 contained 29,904 nucleotides (GenBank accession No: MW004168), Sample 2 (D41, Ct = 35.0) contained fragments totaling 13,499 nucleotides, and Sample 3 (D57, Ct = 25.0) contained fragments totaling 15,556 nucleotides. The complete genomic sequence of Sample 1 was 99.980% identical to SARS-CoV-2 isolate Wuhan-Hu-1 (Genbank accession No: NC_045512.2). The pairwise nucleotide identities of the three clinical samples were 99.970% (Samples 1 vs 2), 99.974% (Samples 1 vs 3), and 99.973% (Samples 2 vs 3) in the approximately 10 kb overlapping region. Growth assays for these three samples were performed to test for infectious virus, and only the sample at D17 (24 days after symptom onset) was viable.

The viruses from all three samples belong to the GH lineage of SARS-CoV-2 (Figure 1D) with D614G in the S protein, P4715L in non-structural protein (nsp) 12, T265I at nsp2, and Q57H at open reading frame 3a (ORF3a), consistent with the prevalent D614G/Q57H/T265I subclade in the United States\(^\text{15}\). A limited number of polymorphisms were identified among these three viruses (Figure 1C). Of note, A4771V at ORF1ab was identified only in Sample 2 but not in Samples 1 and 3.

**Analysis of neutralizing antibodies.** Plasma samples were collected between D29 and D57 for neutralization/inhibition (NI) and ELISA determination (Figure 1A, Table 1). Live SARS-CoV-2-based NI assays showed highly positive and constant Nab titers, ranging from 1:403 to 1:320, until D41. On D52, when the patient retested indeterminate then positive, the Nab geometric mean titer increased to 1:1016, remaining elevated until discharge. Pseudotyped NI results also indicated raised Nab titers on D52. ELISA results showed elevated RBD, S, S1, and S2-specific IgM, IgG, and IgA titers for the first 45 days (Table 1). While other antibodies remained stable or began declining following the first negative test, RBD-specific IgG and S1-specific IgA titers continued rising throughout the hospitalization (Table 1). Elevated RBD-specific IgG and S1-specific IgA titers correlated with the patient retesting positive on D52.

**DISCUSSION**

In current CDC interim guidance on duration of isolation and precautions for adults with COVID-19, persons with severe or critical illness are recommended to be removed from transmission-based precautions 20 days after initial disease onset, at least 24 hours after their last fever without fever-reducing medications, and improved symptoms\(^\text{11}\). Viral shedding in COVID-19 patients can last up to three months after disease onset\(^\text{14}\), but viral shedding is not necessarily correlated with infectious virus\(^\text{16}\). Thus, PCR results are not a sufficient measure for infectivity. In this case report, we show that it is possible for a not immunocompromised patient with severe and persistent COVID-19 symptoms to continue shedding infectious virus beyond 20 days after symptom onset with cell-viability assays, even after the patient had been afebrile for multiple weeks. This patient presented with viable virus growth 24 days after symptom onset, suggesting that patients with severe and persistent COVID-19 may have a longer viral infectivity than originally recognized.
The patient also presented with fluctuating viral loads and increased antibody titers during his severe acute infection and extended persistent infection. A strength of this study is the use of three different serological assays to monitor antibody development. The boosted Nab titers and viral RNA from nasopharyngeal swabs on D52 after a RNA-negative result suggests the patient may have experienced a recurrent infection during his prolonged hospitalization. With high sequence identities among three viruses and a limited number of polymorphisms (Figure 1D), the patient likely experienced a recurrent or persistent infection. It is possible that the negative test may have been a false-negative test or a second infection, which may have been caused by reactivated viruses in this patient, even while the patient’s symptoms improved. Intriguingly, only RBD-specific IgG and S1-based IgA titers clearly increased via ELISA during the recurrent infection period, consistent with Nab titers using live virus (Table 1). Although the pseudotyped NI assay detected Nabs, potential discrepancies from the live virus-based NI assay, as in this study, indicate that caution is needed when interpreting pseudotyped NI data. Overall, our serological and genomic tests were used to determine that this patient demonstrated viable virus growth at least 24 days after symptom onset and experienced elevated neutralizing antibodies during the later stages of his disease.

The primary limitation of this study is that the available data encompasses a single patient. Confounding factors include the multiple pharmaceutical treatments in addition to fluid maintenance and pain control (Supplementary Table 1) that the patient received. Bacterial pneumonia was treated with broad spectrum antibiotics from D3-42. Antifungals were given to treat oral candidiasis D45-56, and methylprednisolone (steroid) was administered from D45-56 for eosinophilic bronchiolitis. In summary, the patient was on steroid medication and had just completed antifungal therapy when they retested positive for SARS-CoV-2 between D54-56.

In summary, this report follows the clinical and serological timeline of a patient with severe and persistent COVID-19. This patient demonstrated viable virus growth at least 24 days after symptom onset. These findings suggest that separate discontinuation of transmission-based precaution guidelines for patients with persistent symptoms and extended hospital stays may be necessary.

Acknowledgments
We are grateful for the facility and technical support from Jeffery Adamovicz, Travis McCarthy, Paul Anderson, and Jeff Whyte at University of Missouri-Columbia. JH and TL were supported by the Global Emerging Infections Surveillance and Response System (GEIS), Division of the Armed Forces Health Surveillance Branch. H. X. has been supported by CBER/FDA intramural COVID19 research fund.

Funding Statement and Conflicts of Interest
This work was supported by National Institutes of Health [5T32LM012410] and Global Emerging Infections Surveillance Branch of the Armed Forces Health Surveillance Division [ProMIS ID P0140_20_WR_01.Global]. The authors have no conflicts of interest to report. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting true views of the US Department of the Army, the US Department of Defense, the US Department of Health and Human Services, or University of Missouri-Columbia.
Author contributions

References

This article is protected by copyright. All rights reserved.

**Table 1.** Comparison of neutralizing antibodies using microneutralization assays with live SARS-CoV-2 virus, neutralization analyses with pseudovirus expressing spike proteins, and ELISA assays. NI-live assays were performed in triplicate, and geometric mean values were calculated. NI-pseudo assays were performed in triplicate, and titers were calculated using regression analyses to correspond to 50% inhibition. ELISA assays were performed in duplicate, and the mean values were calculated. NI-live, Neutralization inhibition assays using live virus; NI-Pseudo, Neutralization inhibition assays using pseudovirus; - , not available; GMT, geometric mean titer; SD, standard deviation.

<table>
<thead>
<tr>
<th>Day</th>
<th>NI-live GMT (±SD)</th>
<th>NI-pseudo GMT (Mean Titers)</th>
<th>ELISA (Mean Titers)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>RBD</td>
<td>S (Full length)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IgG</td>
<td>Ig M</td>
</tr>
<tr>
<td>29</td>
<td>403 (±1.49)</td>
<td>8600</td>
<td>8100 300 90 0</td>
</tr>
<tr>
<td></td>
<td>320 (±1.00)</td>
<td>10148</td>
<td>8100 300 90 0</td>
</tr>
<tr>
<td>35</td>
<td>508 (±1.49)</td>
<td>7287</td>
<td>8100 300 90 0</td>
</tr>
<tr>
<td></td>
<td>806 (±1.49)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>41</td>
<td>1016 (±1.49)</td>
<td>10746</td>
<td>8100 100 90 0</td>
</tr>
<tr>
<td>46</td>
<td>1016 (±1.49)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>52</td>
<td>1016 (±1.49)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>53</td>
<td>1016 (±1.49)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>56</td>
<td>1016 (±1.49)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>57</td>
<td>-</td>
<td>8773</td>
<td>1620 0 100 30 0</td>
</tr>
<tr>
<td>Negative control</td>
<td>&lt;1:40</td>
<td>&lt;1:40</td>
<td>50 50 50</td>
</tr>
</tbody>
</table>
**Figure Legend**

**Figure 1. Time course of clinical, virological, and immunological responses in a COVID-19 patient with a prolonged clinical course.** A) Clinical outcomes, SARS-CoV-2 infections, and neutralizing antibody responses demonstrate the course of clinical improvement and are associated with the elevation of neutralizing antibodies and occurrence of apparent re-infection. ER, emergency room; ICU, intensive care unit; PEG, percutaneous endoscopic gastrostomy; N, nasopharyngeal swab; P, plasma; +, SARS-CoV-2 positive by RT-PCR; -, SARS-CoV-2 negative by RT-PCR; u, SARS-CoV-2 inconclusive by RT-PCR; GMT, geometric mean titer; NI Titers, neutralizing titers. The dashed line denotes the titer of 1:40 which was used to define seroconversion.; B) CT chest demonstrates diffuse bilateral ground glass opacities (white arrow) and patchy areas of subpleural consolidation (black arrow) (left image, Day 29), and follow-up CT chest (right, Day 40) shows interval improvement in the airspace opacities. C) Summary of amino acid mutations in the viruses from clinical samples 1, 2, and 3. D) Phylogenetic tree of the viruses with complete genomes. The phylogenetic tree was rooted with the SARS-CoV-2 isolate Wuhan-Hu-1 (Genbank accession No: NC_045512.2) (color in blue). Bayesian posterior probabilities are indicated in the nodes. Scale bar shows the average number of substitutions per nucleotide site. The sequences from three clinical samples are colored in red.